EUCTR2015-003873-13-GR进行中（未招募）1 期
Evaluation of the tubular effects of dapagliflozin using 1HNMR spectroscopy.
Institute for the Study, Research and Education in Diabetes Mellitus and Metabolic Disorders0 个研究点目标入组 50 人开始时间: 2015年10月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent prior to any study specific procedures
- •2. Female and/or male aged 18-70 years. Women with childbearing potential can only be included in the study if a serological pregnancy test is negative and a safe contraception method is used throughout the study.
- •3. Uncontrolled type 2 diabetes mellitus (HbA1c > 7%) on metformin monotherapy (= 2000 mg qd or maximum tolerated dose)
- •4. Stage 1 hypertension (BP 140-159/90-99 mmHg)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •1. Known primary kidney disease (eGFR < 60 ml/min)
- •2. History of cardiovascular disease
- •3. Type 1 diabetes
- •4. History of heart failure
- •5. Diseases that shorten the life expectancy (cancers, degenerative neurological disorders etc.)
- •6. Pregnancy-lactation
- •7. Patients with eGFR values lower than 45 ml/min (on repeated measurements) during the study period will be excluded
研究者
相似试验
已完成
4 期
Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR SpectroscopyDiabetesNCT02798757University of Ioannina50
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003897-41-DKAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-BGAstraZeneca AB4,500
已完成
3 期
DAPA-HFChronic Heart Failure With Reduced Ejection Fraction (HFrEF)JPRN-jRCT2080223469AstraZeneca KK330